Storys aus Tübingen
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
mehrAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
mehrEnergy at its best: German battery pioneer CustomCells unveils new brand identity
mehrPress Release: Instone sells 105 predominantly subsidized apartments in the "Neckar.Au Viertel" to the city of Rottenburg am Neckar
Ein DokumentmehrHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
mehrHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
mehrHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
mehrProject TwinTrace: Customcells works together with partners on a smart battery factory
mehrCustomcells strengthens sustainable battery industry ‘Made in Germany’
mehrHearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
mehrGerman battery pioneer closes Series A financing round: 60 million euros for Customcells
mehrHearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will present data on its lead candidates — clinical stage ACOU085 and late ...
mehrCUSTOMCELLS publishes future theses for Germany's battery industry
mehrCellforce Group lays foundation for modern, sustainable battery production in Europe
mehr10 years of CUSTOMCELLS: Battery cell specialist ready for the next phase of growth
mehrBattery innovator's new CEO / Dirk Abendroth joins CUSTOMCELLS' Board of Management
mehrAcousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston
Tübingen (ots) - Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20–23, 2022. ACOU085 is a proprietary, first-in-class, small-molecule ...
mehrThe year of battery cell technology: CUSTOMCELLS expects massive growth in 2022
mehrCUSTOMCELLS brings three new shareholders on board following funding round
mehrCellforce Group GmbH: Joint Venture between Porsche and CUSTOMCELLS
mehrTechnische Universität München
A molecular map for the plant sciences
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/ High resolution images: https://mediatum.ub.tum.de/1540641 NEWS RELEASE First comprehensive map of the proteome of the model plant Arabidopsis thaliana A molecular map for the plant sciences Plants are essential for ...
mehrTechnische Universität München
The GERDA-Collaboration: Major steps forward in understanding neutrino properties
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: http://www.tum.de/nc/die-tum/aktuelles/pressemitteilungen/details/35672/ High resolution images: https://mediatum.ub.tum.de/1518985 NEWS RELEASE Closing in on elusive particles Major steps forward in understanding ...
mehrTwo-pronged approach - Novel combined therapy tackles excess fatty tissue
A new combined therapy for obesity and diabetes has been shown to suppress the appetite and at the same time increase energy expenditure. Scientists from the Helmholtz Zentrum München and the Technical University of Munich (TUM), partner institutions of the German Center for ...
mehr